- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 9, 2019
Highlights
- Market Cap
- $6.51M
- Enterprise Value
- $37.08M
- EPS (TTM)
- -$1.61
- Gross Profit (TTM)
- -$71.00K
- EBITDA (TTM)
- -$58.07M
- Year Range
- $15.10 - $909.98
- ROA (TTM)
- -89.80%
- ROE (TTM)
- 235.14%
- Avg. Volume (1M)
- 37K
- Avg. Volume Value (1M)
- $709.42K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
QNCX Performance Chart
Cortexyme Inc (QNCX) is down 96.5% since the beginning of the year. At $23 per share, QNCX is trading 97.4% below its 52-week high of $910. Investors who bought $1,000 worth of QNCX shares 5 years ago would now be looking at an investment worth $2.
Loading charts...
Compare this symbol against anything
Returns By Period
Cortexyme Inc (QNCX) has returned -96.51% so far this year and -93.04% over the past 12 months.
Cortexyme Inc
- 1D
- 1.56%
- 1M
- 35.75%
- 6M
- -31.21%
- YTD
- -96.51%
- 1Y
- -93.04%
- 3Y*
- -54.11%
- 5Y*
- -70.95%
- 10Y*
- —
- ALL TIME*
- -50.96%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
QNCX Monthly Returns History
Based on dividend-adjusted daily data since May 9, 2019, QNCX's average daily return is +0.15%, while the average monthly return is +1.65%. At this rate, an investment would double in approximately 3.5 years.
Historically, 44% of months were positive and 56% were negative. The best month was Nov 2025 with a return of +121.2%, while the worst month was Jan 2026 at -94.9%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 9 months.
On a daily basis, QNCX closed higher 46% of trading days. The best single day was Feb 10, 2026 with a return of +306.2%, while the worst single day was Jan 29, 2026 at -91.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -94.93% | -26.06% | -19.33% | 29.19% | -12.21% | -20.91% | 28.59% | -96.51% | |||||
| 2025 | -13.90% | -9.94% | -8.28% | -17.29% | -5.45% | 58.65% | 2.42% | -5.33% | 1.87% | 1.23% | 121.21% | -8.22% | 79.14% |
| 2024 | 18.10% | 4.84% | -18.46% | 0.94% | -22.43% | -9.64% | -0.01% | -7.85% | 12.33% | 108.71% | 26.54% | -8.78% | 78.10% |
| 2023 | 53.75% | -5.35% | 68.18% | -1.92% | -1.96% | 0.33% | -20.27% | 9.17% | -14.50% | -13.34% | -8.30% | 17.98% | 64.73% |
| 2022 | -51.82% | -28.45% | 42.30% | -40.87% | -29.23% | -14.29% | -12.16% | -9.74% | -24.43% | -24.81% | -26.30% | -13.51% | -94.95% |
| 2021 | 41.18% | -13.13% | 5.75% | 8.71% | 5.62% | 28.11% | 6.62% | 70.41% | -4.82% | -85.60% | -1.44% | -3.00% | -54.57% |
Benchmark Metrics
Cortexyme Inc has an annualized alpha of 27.15%, beta of 0.92, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since May 09, 2019.
- This stock participated in 182.67% of S&P 500 Index downside but only -60.21% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 27.15%
- Beta
- 0.92
- R²
- 0.01
- Upside Capture
- -60.21%
- Downside Capture
- 182.67%
Return for Risk
Risk / Return Rank
QNCX ranks 38 for risk / return — above 38% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Cortexyme Inc (QNCX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| QNCX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.68 | ||
| Sortino ratioReturn per unit of downside risk | -0.66 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.25 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | -0.95 | 2.00 | -2.95 |
| Martin ratioReturn relative to average drawdown | -1.33 | 8.49 | -9.82 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cortexyme Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cortexyme Inc was 99.93%, occurring on Mar 20, 2026. The portfolio has not yet recovered.
The current Cortexyme Inc drawdown is 99.90%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.93%Mar 2026 | 4y 7mo | — | 4y 11moAug 2021 - now | — |
-61.69%Dec 2020 | 10mo 17d | 7mo 11d | 1y 5moFeb 2020 - Aug 2021 | — |
-56.16%Aug 2019 | 1mo 29d | 3mo 21d | 5mo 20dJul 2019 - Dec 2019 | — |
-38.11%Jan 2020 | 14d | 1mo 8d | 1mo 22dDec 2019 - Feb 2020 | — |
-27.46%May 2019 | 1d | 1mo 8d | 1mo 8dMay 2019 - Jun 2019 | — |
Drawdown Indicators
| QNCX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.93% | -56.78% | -43.15% |
Max Drawdown (1Y)Largest decline over 1 year | -98.18% | -9.10% | -89.08% |
Max Drawdown (3Y)Largest decline over 3 years | -98.18% | -18.90% | -79.28% |
Max Drawdown (5Y)Largest decline over 5 years | -99.93% | -25.43% | -74.50% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.90% | -1.58% | -98.32% |
Average DrawdownAverage peak-to-trough decline | -76.61% | -10.70% | -65.91% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 69.99% | 2.14% | +67.85% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cortexyme Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Cortexyme Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with QNCX
Add Cortexyme Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with QNCX